The Champalimaud Foundation has installed Lonza's MODA-ES platform at its clinical centre in Lisbon, Portugal.
The biomedical research organisation plans to use the equipment to optimise and streamline the cell therapy manufacturing process to improve therapeutic accessibility for patients with cancer.
The Champalimaud Foundation has build a multi-purpose GMP facility to develop novel cell therapies to an industrial standard.
The organisation works in tandem with academic and industry partners, and wants to be transparent with the process for the sake of current and future collaborations.
Lonza's MODA-ES platform was selected because of its specificity to cell and gene therapy production, as well as its batch to batch gathering of quality control data into a single record.
The technology also provides the Champalimaud Foundation with advanced traceability.
Lonza's Senior Vice President and Head of Bioscience, Orla Cloak, commented: “We are committed to supporting our customers in bringing innovative cell and gene therapies to their patients. This commitment relies on our capability to offer the right expertise and tools, including MODA-ES. We are also proud to support our customers with an experienced implementation team that understands the intricacies of cell and gene therapy manufacture and can help to accelerate the path to market for these novel therapies.”
